Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00452387 · ClinicalTrials.gov registry record · Phase 2
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00452387 is a Phase 2 study that was terminated before completion, run by Accelerated Community Oncology Research Network. The registered enrollment target is 22 participants.
The verdict
NCT00452387, a Phase 2 study, was terminated before completion, sponsored by Accelerated Community Oncology Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic hormone-refractory prostate cancer.
Interventions
- DRUG Prednisone
- DRUG Mitoxantrone
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00452387
The ClinicalTrials.gov registry entry for NCT00452387 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT00452387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00452387 about?
NCT00452387 is a clinical study titled "Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)". The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic hormone-refractory prostate cancer.
What is the current status of trial NCT00452387?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00452387?
The interventions under investigation include: Prednisone (DRUG), Mitoxantrone (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00452387?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.